DIABETES THERAPY IN CYSTIC FIBROSIS SUBJECTS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 囊性纤维化相关糖尿病(CFRD)存在于约40%的囊性纤维化成人患者中，并与发病率和死亡率的增加有关。当空腹血糖水平正常时，CFRD患者不进行常规的外源性胰岛素治疗。我们假设，长期使用胰岛素或口服内源性胰岛素刺激剂可以改善无空腹高血糖的成人CFRD患者的肌肉质量和临床状态。这是一项由明尼苏达大学医学博士Antoinette Moran协调的多中心、前瞻性、安慰剂对照干预试验。受试者将接受为期12个月的胰岛素、瑞格列奈或口服安慰剂治疗。将评估这些药物对肌肉质量、体重、身体成分和肺功能的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Cystic Fibrosis Related Diabetes (CFRD) is present in approximately 40% of adult patients with cystic fibrosis and is associated with increased morbidity and mortality. Patients with CFRD are not routinely treated with exogenous insulin when their fasting glucose levels are normal. We hypothesize that chronic treatment with either insulin or an oral stimulator of endogenous insulin will lead to improved muscle mass and clinical status in adult CF patients with CFRD without fasting hyperglycemia. This is a multi-center, prospective, placebo-controlled intervention trial coordinated by Antoinette Moran, M.D. at the University of Minnesota. Subjects will be treated for 12 months with either insulin or repaglinide or an oral placebo. The effects of these agents on muscle mass, body weight, body composition and pulmonary function will be evaluated.